Osmotic demyelination syndrome amidst COVID-19: A case report with literature review

Dimitrov, G.; Naeva, D.; Duparinova, R.; Stratieva, S.; Manev, V.; Prinova, K.

doi:10.1016/j.nrl.2023.11.001

Neurología

2024

DOI: 10.1016/j.nrl.2023.11.001

|View full text |Cite

Osmotic demyelination syndrome amidst COVID-19: A case report with literature review

G. Dimitrov,

D. Naeva,

R. Duparinova

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Syndrome of inappropriate antidiuresis/hyponatremia in COVID-19

Peri,

Naldi,

Norello

et al. 2024

Pituitary

View full text Add to dashboard Cite

Hyponatremia is the most frequent electrolyte alteration among hospitalized patients and it has been reported in 20–40% of patients with SARS-CoV-2 (COVID-19) infection. Multiple causes of hyponatremia have been hypothesized in these patients. The syndrome of inappropriate antidiuresis (SIAD) has been considered one of the main reasons leading to hyponatremia in this condition. SIAD can be secondary to cytokines release, in particular IL-6. Positive pressure ventilation can be another cause of hyponatremia due to SIAD. Other possible etiologies of hyponatremia in COVID-19 patients can be related to secondary hypocortisolism, nausea, vomiting, heart and kidney damage. Similar to many other clinical conditions, there is strong evidence that hyponatremia is associated with a worse prognosis also in patients with COVID-19 infection. In particular, hyponatremia has been identified as an independent risk of ICU transfer, need of non-invasive ventilation and death. Hyponatremia in COVID-19 patients is in principle acute and symptomatic and should be treated as such, according to the published guidelines. Therefore, patients should be initially treated with i.v. hypertonic saline (3% NaCl) infusion and serum [Na+] should be frequently monitored, in order to remain within a safe rate of correction. There is evidence showing that serum [Na+] correction is associated with a better outcome in different pathologies, including COVID-19 infection.

show abstract

Syndrome of inappropriate antidiuresis/hyponatremia in COVID-19

Peri,

Naldi,

Norello

et al. 2024

Pituitary

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Osmotic demyelination syndrome amidst COVID-19: A case report with literature review

Cited by 1 publication

References 15 publications

Syndrome of inappropriate antidiuresis/hyponatremia in COVID-19

Syndrome of inappropriate antidiuresis/hyponatremia in COVID-19

Contact Info

Product

Resources

About